BARD1 Vaccine

BARD1 LSL entered into a collaboration with the Institute for Respiratory Health (IRH) to evaluate a potential BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models.

Stage 1 of the project to identify high BARD1 expressing tumour cell lines for implantation in animals under Animal Ethics Committee approval was completed in Aug-17.

Stage 2 of the project to evaluate the in vivo effectiveness of the BARD1 vaccine formulations for reducing tumour growth in animal models is underway, with the study expected to be completed in late 2018.